GSK: Please, EMA, Can We Have Some More?

Company Is Seeking Another Speedy Review

 
• By Neena Brizmohun and Maureen Kenny

Hot on the heels of winning EU fast-track review status for belantamab mafodotin, GlaxoSmithKline has asked the European Medicines Agency to grant accelerated assessment to another of its planned marketing applications.

View from Side of Car moving in a night city, Blured road with lights with car on high speed. Concept rapid rhythm of a modern city.
GSK wants the EMA to speed up its review of dostarlimab • Source: Shutterstock

More from Europe

More from Geography